An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.

MLA

Papp, K., et al. “An Indirect Comparison of Long‐term Efficacy of Every‐2‐week Dosing vs. Recommended Dosing of Ixekizumab in Patients Who Had Static Physician’s Global Assessment > 1 at Week 12.” British Journal of Dermatology, vol. 183, no. 1, July 2020, pp. 52–59. EBSCOhost, https://doi.org/10.1111/bjd.18550.

APA

Papp, K., Maari, C., Cauthen, A., Gooderham, M., Spelman, L., Yamanaka, K., Polzer, P., Zhang, L., Osuntokun, O., & Augustin, M. (2020). An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician’s Global Assessment > 1 at week 12. British Journal of Dermatology, 183(1), 52–59. https://doi.org/10.1111/bjd.18550

Chicago

Papp, K., C. Maari, A. Cauthen, M. Gooderham, L. Spelman, K. Yamanaka, P. Polzer, L. Zhang, O. Osuntokun, and M. Augustin. 2020. “An Indirect Comparison of Long‐term Efficacy of Every‐2‐week Dosing vs. Recommended Dosing of Ixekizumab in Patients Who Had Static Physician’s Global Assessment > 1 at Week 12.” British Journal of Dermatology 183 (1): 52–59. doi:10.1111/bjd.18550.